Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA6 | P23280 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | TPMT | P51580 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | TTR | P02766 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695867 | 0.84 | CA12 (0.65) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1351481 | 0.80 | HSD17B2 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20057570 | 0.79 | CA12 (0.57) | CA12CA1CA2CA4CA6 | |
| SCHEMBL7674114 | 0.79 | TSHR (0.60) | CA12CA1CA2CA4CA6 | |
| Veratric Acid SCHEMBL976032 | 0.77 | CA12 (1.00) | CA12CA1CA2CA4CA6 | |
| Veratric Acid SCHEMBL114848 | 0.77 | CA12 (1.00) | CA12CA1CA2CA4CA6 | |
| Veratric Acid SCHEMBL29386353 | 0.77 | CA12 (1.00) | CA12CA1CA2CA4CA6 | |
| SCHEMBL27636681 | 0.77 | CA1 (0.52) | CA12CA1CA2CA4CA6 | |
| SCHEMBL27315844 | 0.77 | ACE2 (0.49) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1989676 | 0.76 | TSHR (0.57) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063046-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-1698618-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-15 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7705053-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123493-A1 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1698618-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123493-A1 | Benzamide derivative | BDKRB1, BDKRB2, NR1H2 | CA12 2136/4885CA1 2122/4885CA2 715/4885 |
| US-20100179326-A1 | BENZAMIDE DERIVATIVE | NR0B2, NR1H2, CNR2 | CA12 2416/4885CA1 2737/4885CA2 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.